VO-OHpic | CAS#476310-60-8 | PTEN inhibitor

VO-OHpic
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 562481

CAS#: 476310-60-8

Description: VO-OHpic is an inhibitor of PTEN (phosphatase and tensin homologue deleted on chromosome 10).

Chemical Structure

VO-OHpic

CAS# 476310-60-8

Instruction

Theoretical Analysis

MedKoo Cat#: 562481
Name: VO-OHpic
CAS#: 476310-60-8
Chemical Formula: C12H15N2O11V
Exact Mass: 414.01
Molecular Weight: 414.190
Elemental Analysis: C, 34.80; H, 3.65; N, 6.76; O, 42.49; V, 12.30

Price and Availability

Size	Price	Availability	Quantity
5mg	USD 230
10mg	USD 360
25mg	USD 700
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: VO-OHpic; VO OHpic; VOOHpic;

IUPAC/Chemical Name: Hydroxy(oxo)vanadium 3-hydroxypyridine-2-carboxylic acid complex trihydrate

InChi Key: HCJXRYXYWPOIGP-UHFFFAOYSA-K

InChi Code: InChI=1S/2C6H5NO3.4H2O.O.V/c2*8-4-2-1-3-7-5(4)6(9)10;;;;;;/h2*1-3,8H,(H,9,10);4*1H2;;/q;;;;;;;+3/p-3

SMILES Code: O=[V](OC(C1=NC=CC=C1O)=O)(O)OC(C2=NC=CC=C2O)=O.O.O.O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 414.19 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Zhao Y, Zhao R, Wu J, Wang Q, Pang K, Shi Q, Gao Q, Hu Y, Dong X, Zhang J, Sun J. Melatonin protects against Aβ-induced neurotoxicity in primary neurons via miR-132/PTEN/AKT/FOXO3a pathway. Biofactors. 2018 Jan 11. doi: 10.1002/biof.1411. [Epub ahead of print] PubMed PMID: 29322615.

2: Tsui KH, Chiang KC, Lin YH, Chang KS, Feng TH, Juang HH. BTG2 is a tumor suppressor gene upregulated by p53 and PTEN in human bladder carcinoma cells. Cancer Med. 2018 Jan;7(1):184-195. doi: 10.1002/cam4.1263. Epub 2017 Dec 13. PubMed PMID: 29239139; PubMed Central PMCID: PMC5773943.

3: Wang S, Guan Y, Wang Y, Li H, Zhang D, Ju M, Hao Y, Song X, Sun B, Dou X, Yang R. Reduced PTEN involved in primary immune thrombocytopenia via contributing to B cell hyper-responsiveness. Mol Immunol. 2018 Jan;93:144-151. doi: 10.1016/j.molimm.2017.11.010. Epub 2017 Nov 22. PubMed PMID: 29175594.

4: Tsai CY, Wu JCC, Fang C, Chang AYW. PTEN, a negative regulator of PI3K/Akt signaling, sustains brain stem cardiovascular regulation during mevinphos intoxication. Neuropharmacology. 2017 Sep 1;123:175-185. doi: 10.1016/j.neuropharm.2017.06.007. Epub 2017 Jun 7. PubMed PMID: 28601397.

5: Xi Y, Chen Y. PTEN Plays Dual Roles As a Tumor Suppressor in Osteosarcoma Cells. J Cell Biochem. 2017 Sep;118(9):2684-2692. doi: 10.1002/jcb.25888. Epub 2017 Apr 25. PubMed PMID: 28106296.

6: Yang Z, Liu Y, Shi C, Zhang Y, Lv R, Zhang R, Wang Q, Wang Y. Suppression of PTEN/AKT signaling decreases the expression of TUBB3 and TOP2A with subsequent inhibition of cell growth and induction of apoptosis in human breast cancer MCF-7 cells via ATP and caspase-3 signaling pathways. Oncol Rep. 2017 Feb;37(2):1011-1019. doi: 10.3892/or.2017.5358. Epub 2017 Jan 9. PubMed PMID: 28075472.

7: Bankoglu EE, Tschopp O, Schmitt J, Burkard P, Jahn D, Geier A, Stopper H. Role of PTEN in Oxidative Stress and DNA Damage in the Liver of Whole-Body Pten Haplodeficient Mice. PLoS One. 2016 Nov 28;11(11):e0166956. doi: 10.1371/journal.pone.0166956. eCollection 2016. PubMed PMID: 27893783; PubMed Central PMCID: PMC5125655.

8: Augello G, Puleio R, Emma MR, Cusimano A, Loria GR, McCubrey JA, Montalto G, Cervello M. A PTEN inhibitor displays preclinical activity against hepatocarcinoma cells. Cell Cycle. 2016;15(4):573-83. doi: 10.1080/15384101.2016.1138183. PubMed PMID: 26794644; PubMed Central PMCID: PMC5056616.

9: Bulger DA, Conley J, Conner SH, Majumdar G, Solomon SS. Role of PTEN in TNFα induced insulin resistance. Biochem Biophys Res Commun. 2015 Jun 5;461(3):533-6. doi: 10.1016/j.bbrc.2015.04.063. Epub 2015 Apr 24. PubMed PMID: 25918024; PubMed Central PMCID: PMC4433815.

10: Li J, Wang H, Zhong Q, Zhu X, Chen SJ, Qian Y, Costakis J, Bunney G, Beiser DG, Leff AR, Lewandowski ED, ÓDonnell JM, Vanden Hoek TL. A novel pharmacological strategy by PTEN inhibition for improving metabolic resuscitation and survival after mouse cardiac arrest. Am J Physiol Heart Circ Physiol. 2015 Jun 1;308(11):H1414-22. doi: 10.1152/ajpheart.00748.2014. Epub 2015 Mar 20. PubMed PMID: 25795713; PubMed Central PMCID: PMC4451301.

11: Mak LH, Woscholski R. Targeting PTEN using small molecule inhibitors. Methods. 2015 May;77-78:63-8. doi: 10.1016/j.ymeth.2015.02.007. Epub 2015 Mar 4. Review. PubMed PMID: 25747336.

12: Spinelli L, Lindsay YE, Leslie NR. PTEN inhibitors: an evaluation of current compounds. Adv Biol Regul. 2015 Jan;57:102-11. doi: 10.1016/j.jbior.2014.09.012. Epub 2014 Oct 2. PubMed PMID: 25446882.

13: Zhu X, Shao ZH, Li C, Li J, Zhong Q, Learoyd J, Meliton A, Meliton L, Leff AR, Vanden Hoek TL. TAT-protein blockade during ischemia/reperfusion reveals critical role for p85 PI3K-PTEN interaction in cardiomyocyte injury. PLoS One. 2014 Apr 21;9(4):e95622. doi: 10.1371/journal.pone.0095622. eCollection 2014. PubMed PMID: 24752319; PubMed Central PMCID: PMC3994094.

14: Mak LH, Vilar R, Woscholski R. Characterisation of the PTEN inhibitor VO-OHpic. J Chem Biol. 2010 Oct;3(4):157-63. doi: 10.1007/s12154-010-0041-7. Epub 2010 Jun 4. PubMed PMID: 21643420; PubMed Central PMCID: PMC2957887.

15: Zu L, Shen Z, Wesley J, Cai ZP. PTEN inhibitors cause a negative inotropic and chronotropic effect in mice. Eur J Pharmacol. 2011 Jan 10;650(1):298-302. doi: 10.1016/j.ejphar.2010.09.069. Epub 2010 Oct 14. PubMed PMID: 20951693; PubMed Central PMCID: PMC2997895.

Your view history

VO-OHpic featured